ARO-APOC3
Sponsors
Arrowhead Pharmaceuticals Inc., Arrowhead Pharmaceuticals
Conditions
DyslipidemiasFamilial ChylomicronemiaFamilial Chylomicronemia Syndrome (FCS)HypertriglyceridemiaMixed DyslipidemiaSevere Hypertriglyceridemia
Phase 1
Phase 2
Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
CompletedNCT04720534
Start: 2021-05-31End: 2023-08-31Updated: 2026-03-24
Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia
CompletedNCT04998201
Start: 2021-09-28End: 2023-08-14Updated: 2026-04-14
Study of ARO-APOC3 in Adults With Dyslipidemia
CompletedNCT05413135
Start: 2022-07-07End: 2025-09-22Updated: 2026-05-12
A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia
Not yet recruitingCTIS2024-511331-96-00
Target: 178Updated: 2025-10-20